Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Renita Brown

Infectious Disease Indianapolis, IN Medical Doctor

NPI 1881766475 CMS profile 1185409

7250 Clearvista Drive, Suite 375, Indianapolis, IN 46256

Open in the dashboard

General payments

$11,648

453 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Renita Brown of Indianapolis, IN is reported in the CMS Open Payments database as having received $11,648 across 453 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,280 74
2024 General $2,370 75
2023 General $1,648 52
2022 General $1,412 59
2021 General $1,641 72
2020 General $1,110 61
2019 General $1,187 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Renita Brown
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Renita Brown were reported at $2,280. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Renita Brown Infectious Disease median Middle half National median
2019 $1,187 $190 $60–$862 $163
2020 $1,110 $124 $32–$606 $114
2021 $1,641 $148 $38–$905 $132
2022 $1,412 $166 $50–$834 $149
2023 $1,648 $171 $57–$787 $160
2024 $2,370 $176 $52–$752 $164
2025 $2,280 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,174 60 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,910 118 payments
  3. Janssen Biotech, Inc. $1,240 45 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,024 44 payments
  5. Phathom Pharmaceuticals, Inc. $960 29 payments
  6. Gilead Sciences, Inc. $594 20 payments
  7. E.R. Squibb & Sons, L.L.C. $569 5 payments
  8. Ardelyx, Inc. $412 15 payments
  9. Braintree Laboratories, Inc. $369 22 payments
  10. Pfizer Inc. $349 9 payments
  11. Other $2,047 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,516 448 payments
  2. Education $132 5 payments
Products named General payments · program years 2019–2025
  1. STELARA $1,313 41 payments
  2. XIFAXAN $1,277 79 payments
  3. RINVOQ $1,003 23 payments
  4. ENTYVIO $857 35 payments
  5. VOQUEZNA $790 19 payments
  6. TREMFYA $634 15 payments
  7. SKYRIZI Immunology $616 13 payments
  8. ZEPOSIA $583 6 payments
  9. SKYRIZI Immunology $476 14 payments
  10. IBSRELA $412 15 payments
  11. Other $6,055 290 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

453 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record